Segall Bryant & Hamill LLC Has $23.39 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Segall Bryant & Hamill LLC decreased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 5.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 149,309 shares of the company's stock after selling 7,835 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.52% of Krystal Biotech worth $23,391,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. State Street Corp boosted its holdings in Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company's stock valued at $264,455,000 after purchasing an additional 119,936 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Krystal Biotech in the fourth quarter valued at about $15,989,000. Franklin Resources Inc. grew its position in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after buying an additional 62,178 shares in the last quarter. Braidwell LP increased its stake in Krystal Biotech by 57.4% during the third quarter. Braidwell LP now owns 168,691 shares of the company's stock valued at $30,707,000 after acquiring an additional 61,512 shares during the period. Finally, TimesSquare Capital Management LLC raised its holdings in Krystal Biotech by 39.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company's stock valued at $24,888,000 after acquiring an additional 44,646 shares in the last quarter. Institutional investors own 86.29% of the company's stock.

Remove Ads

Krystal Biotech Stock Up 0.4 %

NASDAQ:KRYS traded up $0.67 on Friday, reaching $183.42. The stock had a trading volume of 81,188 shares, compared to its average volume of 289,327. The company has a market capitalization of $5.28 billion, a P/E ratio of 61.34 and a beta of 0.87. Krystal Biotech, Inc. has a 1-year low of $141.72 and a 1-year high of $219.34. The stock has a fifty day moving average price of $170.11 and a 200-day moving average price of $173.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same period in the prior year, the company earned $0.30 EPS. Krystal Biotech's revenue for the quarter was up 116.4% on a year-over-year basis. Sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.10% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on KRYS. HC Wainwright restated a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target on the stock. Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Citigroup upped their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $220.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).